Researchers reviewed clinical trial data of 19 FDA-approved treatments for non-small cell lung cancer.
In an effort to estimate the years of life lost (YLL) with current non-small cell lung cancer (NSCLC) treatments based on molecular or biomarker subgroup, researchers evaluated all targeted therapies, chemotherapy, and immuno-oncology (IO) regimens approved by the FDA for these patients through March 3, 2021.
Although the findings suggest targeted therapies have paved the way for progress in survival benefits for young patients with NSCLC and actionable mutations, “it is evident that these therapies still leave a wide gap in the YLL in these younger patients compared to generally older individuals with advanced NSCLC without targetable mutations,” authors wrote.
Previous molecular profiling of adenocarcinoma tissue has revealed the presence of targetable mutations, including epidermal growth factor receptor (EGRF), anaplastic lymphoma kinase (ALK) ROS1, MET, RET, BRAF, and ERBB2/HER2, while additional research suggested driver mutations are associated with diagnosis at a younger age.
In the current analysis, treatment response was defined as median duration of response (DOR) reported in clinical trials. To calculate YLL, 78.7 was used as the median US life expectancy.
“To estimate the YLL for each driver mutation, we calculated the difference in the median age of cancer diagnosis for patients with the respective driver mutation and the average age of cancer diagnosis for patients who do not have a driver mutation,” authors explained.
A total of 19 targeted therapies approved by the FDA or recommended by National Comprehensive Cancer Network guidelines were included in the retrospective cross-sectional study.
Analyses revealed:
Researchers also found NSCLC is diagnosed 8 to 23.4 years earlier in patients with mutations, while the percent difference ameliorated in YLL by mutation type was 44.3 (ROS1), 28.2 (EGFR), 22.9 (RET), 20.5 (ALK), 18.8 (BRAF), 6.4 (HER2), and 3.7 (NTRK) in years.
Although data showed several of these therapies can provide durable responses in patients with NSCLC not seen with traditional chemotherapy, authors cautioned patient demographics need to be taken into account and weighed against these benefits.
“Even under the most optimistic scenario with all targeted therapies employed, many of these younger patients still carry a greater burden of YLL compared to those older patients with NSCLC without targetable mutations,” they explained.
Analyses employed may have overestimated the therapeutic benefit of each targeted therapy, marking a limitation to the study. In addition, investigators could not account for changes in treatment resulting from TKI resistance mechanisms and did not include all potential therapies used off-label for NSCLC with actionable mutations.
“The progress made in targeted therapies for advanced NSCLC is commendable and deserves praise, but it is unmistakable that considerable progress is still to be made before patients can bridge the gap in YLL,” authors concluded.
Reference
Benjamin DJ, Haslam A, Gill J, and Prasad V, et al. Targeted therapy in lung cancer: are we closing the gap in years of life lost? Cancer Med. Published online March 22, 2022. doi:10.1002/cam4.4703
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More